Novel Combination Therapy for B-Cell Lymphoma
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify if you must stop taking your current medications. However, certain treatments like biologic agents and radiation are not allowed within 28 days before enrollment, and steroids should be avoided 7 days prior unless necessary. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the drug combination therapy for B-cell lymphoma?
Rituximab, a key component of the combination therapy, has been shown to significantly improve outcomes in B-cell lymphomas like diffuse large B-cell lymphoma and follicular lymphoma when added to chemotherapy. Studies have demonstrated that rituximab enhances response rates, progression-free survival, and overall survival in these conditions.12345
Is the novel combination therapy for B-cell lymphoma safe for humans?
The combination therapy involving Venetoclax and Rituximab has been shown to have a manageable safety profile in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Common side effects include blood-related issues like neutropenia (low white blood cell count), but these are generally manageable with proper care.678910
What makes the novel combination therapy for B-cell lymphoma unique?
This novel combination therapy for B-cell lymphoma is unique because it combines multiple drugs, including rituximab and venetoclax, which target cancer cells in different ways. Rituximab is a monoclonal antibody that targets the CD20 protein on B-cells, while venetoclax helps induce cancer cell death by inhibiting a protein called BCL-2. This multi-faceted approach may enhance treatment effectiveness compared to standard therapies.511121314
What is the purpose of this trial?
The purpose of this study is to find the highest dose of a new drug, in combination with standard drugs, which can be tolerated without causing very severe side effects. The study treatment is new agents in combination with R-GDP or an equivalent regimen.
Research Team
Sarit Assouline
Principal Investigator
The Jewish General Hospital, Montreal QC, Canada
Diego Villa
Principal Investigator
BCCA - Vancouver Cancer Centre, BC, Canada
Tara Baetz
Principal Investigator
Cancer Centre of Southeastern Ontario at Kingston, ON, Canada
Eligibility Criteria
This trial is for adults under 65 with aggressive B-cell lymphoma that's come back or didn't respond to first treatments. They must be fit enough for intensive chemo and a stem cell transplant, have measurable disease, and not have severe heart issues, uncontrolled infections, or other cancers being treated. Women who can get pregnant and men must agree to contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Participants receive increasing doses of the new drug in combination with R-GDP to determine the highest tolerable dose without severe side effects
Treatment
Participants receive the new drug in combination with R-GDP at the determined dose
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cisplatin
- Dexamethasone
- Gemcitabine
- RiTUXimab Injection
- Rituximab SC
- Venetoclax
Cisplatin is already approved in European Union, United States, Canada, Japan for the following indications:
- Testicular cancer
- Ovarian cancer
- Cervical cancer
- Bladder cancer
- Head and neck cancer
- Esophageal cancer
- Lung cancer
- Mesothelioma
- Brain tumors
- Neuroblastoma
- Testicular cancer
- Ovarian cancer
- Cervical cancer
- Bladder cancer
- Head and neck cancer
- Esophageal cancer
- Lung cancer
- Mesothelioma
- Brain tumors
- Neuroblastoma
- Testicular cancer
- Ovarian cancer
- Cervical cancer
- Bladder cancer
- Head and neck cancer
- Esophageal cancer
- Lung cancer
- Mesothelioma
- Brain tumors
- Neuroblastoma
- Testicular cancer
- Ovarian cancer
- Cervical cancer
- Bladder cancer
- Head and neck cancer
- Esophageal cancer
- Lung cancer
- Mesothelioma
- Brain tumors
- Neuroblastoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Canadian Cancer Trials Group
Lead Sponsor
Incyte Corporation
Industry Sponsor
Steven Stein
Incyte Corporation
Chief Medical Officer since 2015
MD from University of Witwatersrand
Hervé Hoppenot
Incyte Corporation
Chief Executive Officer since 2014
MBA from ESSEC Business School
Roche Pharma AG
Industry Sponsor
Dr. Thomas Schinecker
Roche Pharma AG
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University
Dr. Levi Garraway
Roche Pharma AG
Chief Medical Officer since 2019
MD from University of California, San Francisco
AbbVie
Industry Sponsor
Dr. Roopal Thakkar
AbbVie
Chief Medical Officer since 2023
MD from Wayne State University School of Medicine
Robert A. Michael
AbbVie
Chief Executive Officer
Bachelor's degree in Finance from the University of Illinois